Table 4 Results of currently approved CAR-T cell products for B-cell lymphoma
From: Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities
Cell product | Target | Cell dose | Indication | Clinical significance | Complications | References |
|---|---|---|---|---|---|---|
Tisagenlecleucel (Kymriah) | CD19 | 0.1–6 × 108 | R/R DLBCL | ORR 52%, CR 40%, PR 12% | Cytopenias:32% Infections:20% NEs (grade 3 or worse):12%, CRS (grade 3 or worse):22% | [122] |
Axicabtagene ciloleucel (Yescarta) | CD19 | 2 × 106/kg | R/R large B-cell lymphoma | ORR 83%, CR 58% | Pyrexia:87% Anaemia:68% NEs (grade 3 or worse):32% CRS (grade 3 or worse):11% | [123] |
|  |  | 2 × 106/kg | R/R FL | ORR 95%, CR 80% | NEs (grade 3 or worse):19% CRS (grade 3 or worse):11% | [124] |
Brexucabtagene Autoleucel (Tecartus) | CD19 | 2 × 106/kg | R/R MCL | ORR 85%, CR 58% | Cytopenias:94% Infections:32% NEs (grade 3 or worse):31%, CRS (grade 3 or worse):15% | [125] |
Lisocabtagene maraleucel (Breyanzi) | CD19 | 50/100/150 × 106 | R/R large B-cell lymphoma | ORR 73%, CR 53% | Neutropenia:60% Anaemia:37% Thrombocytopenia:27% NEs (grade 3 or worse):10%, CRS (grade 3 or worse):2% | [126] |